AstraZeneca

DUO-E | D9311C00001

NCT04269200

JCP078

Durvalumab With or Without Olaparib as Maintenance Therapy After First-Line Treatment of Advanced and Recurrent Endometrial Cancer (DUO-E)

Status:

Opening Soon

26459-200.png

III

Phase

Line of Therapy.png

1st

Line of Therapy

Disease Stage.png

Advanced / Metastatic

Disease Stage

Target.png

Biomarker(s)

N/A

Investigational

Product

Durvalumab

IgG1k monoclonal antibody

Treatment Arms

o Active Comparator: Arm A (control)

o Experimental: Arm B (durvalumab+placebo)

o Experimental: Arm C (durvalumab+olaparib)